|
第六章、參考文獻
1. Nagaraj, R. H.；Shipanova, I. N.；Faust, M. F. Protein cross-linking by the
maillard reaction. J. Biol. Chem. 1996, 271, 19338–19345.
2.Frye, E. B.；Degenhardt, T. P.；Thorpe, S. R.；Baynes, J. W. Role of the maillard
reaction in aging of tissue proteins. J. Biol. Chem. 1998, 273, 18714–18719.
3. Raj, S. C.；Choudhury, D. Advanced glycation end product：a nephrologist’s
perspective. Am. J. Kkidney Dis. 2000, 35, 365-380.
4. Peppa, M.；Uribarri, J.；Vlassara, H. Glucose, advanced glycation endproducts,
and diabetes complications:what is new and what works. Clin. Diabetes. 2003, 21, 186-187.
5. rphr.endojournals.org.
6. Wautier, J. L.；Guillausseau, P. J. Advanced glycation end products, their receptors
and diabetic angiopathy. Diabetes. Metab. 2001, 27, 535-542.
7. Yamagishi, S.；Nakamura, K.；Imaizumi, T. Advanced glycation endproducts (AGEs) and diabetic vascular complications. Curr. Diab. Rev. 2005, 1, 93-106.
8. Shamsi, F. A.；Partal, A.；Nagaraj, R. H. Immunological evidence for
methylglyoxal-derived modifications in vivo. J. Biol. Chem. 1998, 273,
6928–6936.
9. Glomb, M. A.；Monnier, V. M. Mechanism of protein modification by glyoxal and
glycolaldehyde, reactive intermediates of the maillard reaction. J. Biol. Chem.
1995, 270, 10017-10026.
10. Ahmed, M. U.；Frye, E. B.；Baynes, J. W. N-(Carboxyethyl)lysine, a product of
the chemical modification of proteins by methylglyoxal, increases with age in
human lens proteins. Biochem. J. 1997, 324, 565-570.
11. Ferreira, E. N.；Voit, E. O. A quantitative model of the generation of
Nε-(carboxymethyl)lysine in the maillard reaction between collagen and glucose.
Biochem. J. 2003, 376, 109–121.
12. Kumar, M. S.；Reddy, P. Y.；Kumar, P. A. Effect of dicarbonyl-induced browning
on α-crystallin chaperone-like activity: physiological significance and caveats of
in vitro aggregation assays. Biochem. J. 2004, 379, 273–282.
13. Yamada, H.；Miyata, S.；Igaki, N. Increase in 3-deoxyglucosone levels in diabetic
rat plasma. J. Biol. Chem. 1994, 269( 32 ), 20275-20280.
14. Thornalley, P. J.；Langborg, A.；Minhas, H. S. Formation of glyoxal,
methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose.
Biochem. J. 1999, 344, 109-116.
15. Thornalley, P. J. The glyoxalase system: new developments towards functional
characterization of a metabolic pathway fundamental to biological life.
Biochem. J. 1990, 269, 1-11.
16. Bourajjaj, M.；Stehouwer, C.D.A.；Schalkwijk, C.G. Role of methylglyoxal
adducts in the development of vascular complications in diabetes mellitus.
Biochem. Soc. Trans. 2003, 31, 1400-1402.
17. Oya, T.；Hattori, N.；Mizuno, Y. Methylglyoxal modification of protein.
J. Biol. Chem. 1999, 274(26), 18492–18502.
18. Biemel, K. M.；Reihl, O.；Lederer, M. O. Formation pathways for lysine-arginine
cross-links derived from hexoses and pentoses by maillard processes. J. Biol.
Chem. 2001, 276(26), 23405–23412.
19. Pongor, S.；Ulrich, P. C.；Bencsath, F.A. Aging of proteins: isolation and
identification of a fluorescent chromophore from the reaction of polypeptides
with glucose. Proc. Natl. Acad. Sci. 1984, 81, 2684-2688.
20. Grandhee, S. K.；Monnier, V. M. Mechanism of formation of the maillard protein
cross-link pentosidine. J. Biol. Chem. 1991, 266, 11649-11653.
21. Dyer, D. G.；Blackledge, J. A. Thorpet, S. R.；Baynes , J. W. Formation of
pentosidine during nonenzymatic browning of proteins by glucose. J. Biol. Chem.
1991, 266, 11654-11600.
22. Miyata, S.；Monnier, V. Immunohistochemical detection of advanced
glycosylation end products in diabetic tissues using monoclonal antibody to
pyrraline. J. Clin. Invest. 1992, 89, 1102-1112.
23. Hayase, F.；Nagaraj, R. H.；Njorogeg, F. G.；Monnier, V. M. Aging of proteins:
immunological detection of a glucose-derived pyrrole formed during maillard
reaction in Vivo. J. Biol. Chem. 1989, 263(7), 3758-3764.
24. Vlassara, H.；Place, M. R. Glycoxidation. Asian Journal of Medicine. 2003, 70,
232-241.
25. http://bjo.bmjjournals.com/cgi/content/full/85/6/746
26. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications.
Nature. 2001, 414, 813-820.
27. Fu, S.；Fu, M. X.；Baynes, J. W.；Thopre, S. R.；Dean, R. T. Presence of dopa
and amino acid hydroperoxides in proteins modified with advanced glycation end
products (AGEs) : amino acid oxidation products as a possible source of oxidative
stress induced by AGE proteins. Biochem. J. 1998, 330, 233-239.
28. Verzijl, N.；Degroot, J.；Oldehinkel, E.；Bank, R. A.；Thorpe, S. R.；Baynes, J.
W.；Bayliss, M. T. Age-related accumulation of maillard reaction products in
human articular cartilage collagen. Biochem. J. 2000, 350, 381-387.
29. Biemel, K. M.；Friedl, D. A.；Lederer, M. O. Identification and quantification of
major maillard cross-links in human serum albumin and lens protein. J. Biol.
Chem. 2002, 277, 24907–24915.
30. Araki, N.；Uenos, N.；Chakrabartis, B.；Morino, Y.；Horiuchi, S. Immunochemical
evidence for the presence of advanced glycation end products in human lens
proteins and its positive correlation with aging. J. Biol. Chem. 1992, 267,
10211-10214.
31. Miyata, T.；Inagi, R.；lida, Y.；Sato, M.；Yamada, N.；Oda, O.；Maeda, K.；
Seo, H. Involvement of microglobulin modified with advanced glycation end
products in the pathogenesis of hemodialysis-associated amyloidosis. J. Clin.
Invest. 1994, 93, 521-528.
32. Dyer, D. G.；Dunn, J. A.；Thorpe, S. R.；Bailie, K. E.；Lyons, T. J.；Baynes, J.
W. Accumulation of maillard reaction products in skin collagen in diabetes and
aging. J. Clin. Invest. 1993, 91, 2463-2469.
33. Lyons, T. J.；Bailie, K. E.；Dyer, D. G.；Dunn, J. A.；Baynes, J. W. Decrease in
skin collagen glycation with improved glycemic control in patients with
insulin-dependent diabetes mellitus. J. Clin. Invest. 1991, 87, 1910-1915.
34. Ramasamy, R.；Vannucci, S. J.；Yan, S. S.；Herold, K.；Yan, S. F.；Schmidt, A.
M. Advanced glycation end products and RAGE: a common thread in aging,
diabetes, neurodegeneration, and inflammation.Glycobiology. 2005, 15 (7),
16R–28R.
35. Stein, G.；Schiel, R. Diabetes mellitus and dialysis. Am. J. Kidney Dis. 2004, 56,
289-303.
36. Jakus, V.；Rietbrock, V. Advanced glycation end-products and the progress of
diabetic vascular complications. Physiol. Res. 2004, 53, 131-142.
37. Stitt, A. W. The maillard reaction in eye diseases. Ann. N. Y. Acad. Sci. 2005, 1043,
582-597.
38. Schinzel, R. Advanced glycation end products and nutrition. Physiol. Res. 2002,
51, 313-316.
39. Forbes, J. M.；Cooper, M. E.；Oldfield, M. D.；Thomas, M. C. Role of advanced
glycation end products in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14,
S254–S258.
40. Williams, M.D. Clinical studies of advanced glycation end product inhibitors and
diabetic kidney disease. Current Science. 2004, 4, 441–446.
41. Bloomgarden, Z. T. Nephropathy. Diabetes Care. 2001, 24, 598-601.
42. Cooper, M. E.；Bonnet, F.；Oldfield, M. Mechanisms of diabetic vasculopathy: an
overview. Am. J. Hypertens. 2001, 14, 475–486.
43. Smith, M. A.；Taneda, S.；Richey, P. L.；Miyata, S.；Yan, S. D.；Stern, D.；Monnier,
V. M.；Perry, G. Advanced maillard reaction end products are associated with
alzheimer disease pathology. Proc. Nati. Acad. Sci. 1994, 91, 5710-5714.
44. http://alteon.com/cross1.htm
45. Susic, D.；Varagic, J. Crosslink breakers：a new approach to cardiovascular
therapy. Curr. Opin. Cardiol. 2004, 19, 336-340.
46. http://www.vrp.com/art/765.asp
47. Smit, A. J.；Lutgers, H. L. The clinical relevance of advanced glycation
endproducts（AGE）and recent developments in pharmaceutics to reduce AGE
accumulation. Curr. Med. Chem. 2004, 11, 2767-2784.
48. Schinzel, R.；Riederer, P. AGEs in brain ageing: AGE-inhibitors as
neuroprotective and anti-dementia drugs. Biogerontology. 2001, 2, 19–34.
49. Li, Y. M.；Steffest, M.；Donnelly, T.；Basgent, J.；Vlassara, H. Prevention of
cardiovascular and renal pathology of aging by the advanced glycation inhibitor
aminoguanidine. Proc. Natl. Acad. Sci. 1996, 93, 3902-3907.
50. Cantini, C.；Kieffer, P.；Corman, B.；Limiñana, P.；Atkinson, J. Aminoguanidine
and aortic wall mechanics, structure, and composition in aged rats. Hypertension.
2001, 38, 943-948.
51. Usta, M. F.；Sell, D. R.；Monnier, V. M. The protective effect of
aminoguanidine on erectile function in streptozotocin diabetic rats. J. Urol. 2003,
170, 1437–1442.
52. Rashid, G.；Luzon, A. A.；Korzets, Z.；Klein, O.；Zeltzer, E.；Bernheim, J. The
effect of advanced glycation End-products and aminoguanidine on TNFa
production by rat peritoneal macrophages. Perit. Dial. Int. 2001, 21, 122–129.
53. Kelly, D. J.；Koerner, S. M.；Jaworski, K.；Davis, B.；Thallas, V.：Cooper, M.
E. ALT-946 and Aminoguanidine, inhibitors of advanced glycation, improve
severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes. 2002, 51, 3283-3289.
54. Beisswenger, P. J.；Howell, S. K.；Touchette, A. D.；Lal, S.；Szwergold, B. S.
Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes.
1999, 48, 198–202.
55. Standeven, K. F.；Arie¨ns, R. A.；Whitaker, P.；Ashcroft, A. E.；Weisel, J. W.；
Grant, P. J. The effect of dimethylbiguanide on thrombin activity, FXIII
activation, fibrin polymerization, and fibrin clot formation. Diabetes. 2002, 51,
189-197.
56. Hollenbach, S.；Thampi, P. Cleavage of in vitro and in vivo formed lens protein
cross-links by a novel cross-link breaker. Mol. Cell. biochem. 2003, 243, 73-80.
57. Bakris, G. L.；Bank, A. J.；Kass, D. A. Advanced glycation end-product cross-link
breakers. J. Clin. Hypertens. 2004, 17, 23-30.
58. Zile, M. R.；Degroof, R. C. The effect of alagebrium chloride（ALT-711）,a novel glucose cross-link breaker, in the treatment of elderly patients
with diastolic heart failure. J. Card. Fail. 2005, 11, 191-195.
59. Kass, D. A.；Shapiro, E. P. Improved arterial compliance by a novel advanced
glycation end-product crosslink breaker. Circulation. 2001, 104, 1464-1470.
60. Cooper, M. E.；Thallas, V.；Forbes, J.；Scalbert, E.；Sastra, S.；Darby, I.；Soulis,
T. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular
advanced glycation end-product accumulation. Diabetologia. 2000, 43, 660-664.
61. Doggrell, S. A. ALT-711 decreases cardiovascular stiffness and has potential in
diabetes, hypertension and heart failure. Exp. Opin. Invest. Drugs. 2001, 10,
981-983.
62. Voziyan, P. A.；Metz, T. O.；Baynes, J. W.；Hudson, B. G. A post-amadori
inhibitor pyridoxamine also inhibits chemical modification of proteins by
scavenging carbonyl intermediates of carbohydrate and lipid degradation. J. Biol.
Chem. 2002, 277, 3397-3403.
63. Degenhardt, T. P.；Alderson, N. L.；Arrington, D. D.；Beattie, R. J. Pyridoxamine
inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.
Kidney Int. 2002, 61, 939–950.
64. Metz, T. O.；Alderson, N. L.；Chachich, M. E.；Thorpe, S. R.；Baynes, J. W.
Pyridoxamine traps intermediates in lipid peroxidation reactions in Vivo.
J. Biol. Chem. 2003, 278 (43), 42012–42019.
65. Onorato, J. M.；Jenkins, A. J.；Thorpe, S. R.；Baynes, J. W. Pyridoxamine, an
inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation
reactions. J. biol. chem. 2000, 275( 28 ), 21177–21184.
66. Feldman, E. L. Oxidative stress and diabetic neuropathy. J. Clin. Invest. 2003,
111, 431-433.
67. Miyata, T.；Maeda, K.；Kurokawa, K. Oxidation conspires with glycation to
generate noxious advanced glycation end products in renal failure.
Nephrol. Dial. Transplant. 1997, 12, 255–258.
68. Thorpe, S. R.；Baynes, J. W. Oxidative degradation of glucose adducts to protein.
J. Biol. Chem. 1988, 263(18), 816-8821.
69. Zhang, J.；Slevin, M.；Duraisamy, Y.；Gaffney, J.；Ahmed, N. Comparison of
protective effects of aspirin, d-penicillamine and vitamin E against high
glucose-mediated toxicity in cultured endothelial cells.
Biochim. Biophys. Acta. 2006, 1762, 551-557.
70. Floyd, R. A. Antioxidants, oxidative stress,and degenerative neurological
disorders. Exp. Biol. Med. 1999, 222, 236-245.
71. Miyata, T.；Ueda, Y. Mechanism of the inhibitory effect of OPB-9195
[(6)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on advanced
glycation end product and advanced lipoxidation end product formation. J. Am.
Soc. Nephrol. 2000, 11, 1719–1725.
72. Yamamoto, Y.；Kato, I. Development and prevention of advanced
diabetic nephropathy in RAGE-overexpressing mice. J. Clin. Invest. 2001,
108, 261–268.
73. Asif, M.；Egan, J.；Vasan, S.；Lopez, S.；Williams, C.；Ulrich, P. An advanced
glycation endproduct cross-link breaker can reverse age-related increases in
myocardial stiffness. Proc. Natl. Acad. Sci. 2000, 97( 6), 2809–2813.
74. Vasan, S.；Zhang, X.；Ulrich P. An agent cleaving glucose-derived protein
crosslinks in vitro and in vivo. Nature. 1996, 382, 275-278
75. Matsuda, H.；Wang, T. Structural requirements of flavonoids for inhibition of
protein glycation and radical scavenging activities. Bioorg. & Med. Chem. 2003,
11, 5317-5323.
76. Morimitsu, Y.；Yoshida, K. Protein glycation inhibitors from thyme（thymus
vulgaris）. Biosci. Biotech. Biochem. 1995, 59, 2018-2021.
77.Winter, C.A.；Risley, E.A.；Nuss, G.W. Carrageenin-induced edema in hind paw of
the rat as an assay for anti-inflammatory drugs. Proc. Soc. Exp. Biol. Med. 1962,
111, 544-547.
78. Rosa, M.D. Biological properties of carrageenan. J. Pharm. Pharmacol. 1972, 24,
89-102.
79.Rosa, M.；Sorrentino, L. The mechanism of the inflammatory effect of carrageenin. Eur. J. Pharmacol. 1968, 4(3), 340-342.
80.http://www.med.sc.edu:85/ghaffar/innate.htm
81.Goodman, G. The pharmacological basis of therapeutics, 9th ed. 1996.
82.Vinegar, R.；Schreiber, W.；Hugo, R. Biphasic development of carrageenin edema
in rats. J. Pharmacol. Exp. Ther. 1969, 166(1), 96-103.
|